The CFRI CF Community Voices Podcast

Athletes of the Transplant Games - Part 1

In this inspiring podcast, meet several phenomenal athletes with CF, all of whom have received double lung transplants, who share their experiences participating in the Transplant Games. These games provide transplant recipients to honor their donors and demonstrate what their gift means to them. The Transplant games bring out the best in everyone. Watch and be inspired!

If you watch this episode, please let us know what you think at https://www.surveymonkey.com/r/KGB7PKY

CF Community Voices is made possible through grants from Chiesi USA, Genentech, Vertex Pharmaceuticals, Gilead Sciences, and Viatris.

A Conversation on the Impact of Salt in My Soul

In this webinar, recorded on August 23, 2022, Diane Shader Smith, director Will Battersby, and medical ethnographer Rebecca Mueller, PhD, met online for a dynamic discussion about the impact of the documentary film, Salt In My Soul. How has the film impacted viewers globally? What has been its broader impact upon antimicrobial resistance research and awareness? After a roundtable discussion, questions from the audience were answered.

If you watch this episode, please let us know what you think at https://www.surveymonkey.com/r/KGB7PKY

CF Community Voices is made possible through grants from Chiesi USA, Genentech, Vertex Pharmaceuticals, Gilead Sciences, and Viatris.

Transplantation of Gene Edited Upper Airway Basal Stem Cells - Sriram Vaidyanathan, PhD

Dr. Sriram Vaidyanathan, a postdoctoral scholar at the Porteus lab at Stanford University, presents results from CFRI-funded research on identifying biomaterials that enable the transplantation of gene corrected airway stem cells to treat CF. He presents findings from experiments transplanting upper airway basal stem cells into immunocompromised mice using fibrinogen-based scaffolds. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Understanding Gastrointestinal Cancers in Cystic Fibrosis – Christine Hachem, MD

Dr. Christine Hachem, Professor of Medicine in the Division of Gastroenterology at Saint Louis University, presents an overview on GI cancers with cystic fibrosis. With improvements in therapies for CF, there has been an increase in GI cancers in people with CF, the most common of which is colorectal cancer. Dr. Hachem details the epidemiology, etiology and risk factors for GI cancers in CF, as well as current screening recommendations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Role of CFTR Arginine-933 in Channel Function and Potentiator Binding and Efficacy – Stephen Aller, PhD

Dr. Stephen Aller, Associate Professor at the Department of Pharmacology and Toxicology at the University of Alabama at Birmingham, presents results from CFRI-funded research on the role of CFTR Arginine-933 in folding, gating and potentiator drug binding. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Transplantation of Gene Edited Upper Airway Basal Stem Cells - Sriram Vaidyanathan, PhD (Audio)

Dr. Sriram Vaidyanathan, a postdoctoral scholar at the Porteus lab at Stanford University, presents results from CFRI-funded research on identifying biomaterials that enable the transplantation of gene corrected airway stem cells to treat CF. He presents findings from experiments transplanting upper airway basal stem cells into immunocompromised mice using fibrinogen-based scaffolds. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Understanding Gastrointestinal Cancers in Cystic Fibrosis – Christine Hachem, MD (Audio)

Dr. Christine Hachem, Professor of Medicine in the Division of Gastroenterology at Saint Louis University, presents an overview on GI cancers with cystic fibrosis. With improvements in therapies for CF, there has been an increase in GI cancers in people with CF, the most common of which is colorectal cancer. Dr. Hachem details the epidemiology, etiology and risk factors for GI cancers in CF, as well as current screening recommendations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Role of CFTR Arginine-933 in Channel Function and Potentiator Binding and Efficacy – Stephen Aller, PhD (Audio)

Dr. Stephen Aller, Associate Professor at the Department of Pharmacology and Toxicology at the University of Birmingham in Alabama, presents results from CFRI-funded research on the role of CFTR Arginine-933 in folding, gating and potentiator drug binding. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Follow-Up Q&A on Partnership in CF Care: Complementary Therapies – Hanna Phan, PharmD, FCCP, FPPA (Audio)

At Dr. Phan's conference presentation on complementary therapies (which can be viewed here) there was not enough time to address all questions, so Dr. Phan recorded a follow-up podcast to answer all the questions submitted by conference attendees.

If you watch this episode, please let us know what you think at https://www.surveymonkey.com/r/KGB7PKY

CF Community Voices is made possible through grants from Chiesi USA, Genentech, Vertex Pharmaceuticals, Gilead Sciences, and Viatris.

Pseudomonas aeruginosa Diversifies Inside Cells to Form an Adaptive Niche that Resists Antibiotic Treatment – Naren Gajenthra Kumar, BTech, PhD

Dr. Naren G. Kumar, a postdoctoral research scholar at the University of California Berkeley, presents results from CFRI-funded research on characterizing the intracellular diversification of Pseudomonas aeruginosa in chronic lung infections. Findings from experiments suggest that P. aeruginosa undergoes adaptive phenotypic changes in response to the intracellular microenvironment that favor the development of antibiotic-resistant sub-populations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.